Data are reviewed from the phase 3 IMbrave150 trial for unresectable hepatocellular carcinoma.
Durvalumab/Bevacizumab Shows Clinically Meaningful PFS Improvement in HCC
November 9th 2023The phase 3 EMERALD-1 trial has met its primary end point and continues to assess durvalumab combined with transarterial chemoembolization and bevacizumab for the secondary end point of overall survival in patients with hepatocellular carcinoma.
Read More
SD-101 and Checkpoint Blockade Shows Early Favorable Outcomes in UMLM
November 6th 2023Encouraging progression-free survival and ctDNA molecular response rates were seen with SD-101 delivered via pressure-enabled drug delivery plus intravenous checkpoint inhibitors in patients with metastatic uveal melanoma with liver metastases.
Read More
New Therapies to Improve Outcomes for Patients With Intrahepatic Cholangiocarcinoma
October 28th 2023In an interview with Targeted Oncology, Rachna T. Shroff, MD, MS, FASCO, discussed new systemic therapies that are available or being developed to treat patients with intrahepatic cholangiocarcinoma.
Read More